Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2021-03-15 Annual Report
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团2020年年度报告
Annual Report Classification · 100% confidence The document is titled "2020 年年度报告" which translates to "2020 Annual Report". It contains detailed financial data, company overview, business summary, management discussion and analysis, and audited financial statements. The presence of an audit report with an unqualified opinion is mentioned, and the document is extensive (249 pages). The content includes comprehensive financial performance, business operations, risk disclosures, and corporate governance information typical of an annual report. There is no indication that this is merely an announcement or a summary; it is the full report itself. Therefore, the document fits the definition of an Annual Report (10-K). FY 2020
2021-03-15 Chinese
关于公司全资子公司昆药集团医药商业有限公司收购的部分子公司2020年度业绩承诺实现情况的专项审核报告
Audit Report / Information Classification · 95% confidence The document is a detailed audit report focusing on the verification of performance commitments related to subsidiaries of Kunming Pharmaceutical Group Co., Ltd. It includes specific audit opinions, references to Chinese CPA standards (e.g., "China CPA Other Assurance Standards No. 3101"), and detailed financial performance data for multiple years (2017-2020). The document is titled as a "Special Audit Report" (专项审核报告) and contains audit opinions on the accuracy and fairness of performance commitment fulfillment. It is not a full annual report but a standalone audit report related to specific performance commitments and their verification. The document is lengthy (over 12,000 characters) and contains substantive financial data and audit procedures, not merely an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR). FY 2020
2021-03-15 Chinese
昆药集团关于公司2021年与控股股东日常关联交易预估的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's estimated related party transactions with its controlling shareholders for the year 2021. It includes descriptions of the nature of these transactions, approval procedures, financial data of related parties, and assurances about the fairness and impact of these transactions on the company and its shareholders. The document is an official announcement (公告) and does not contain comprehensive financial statements or full financial performance reports. It is focused on disclosure of related party transactions and their estimated amounts, which is typical for regulatory compliance announcements about related party dealings. It is not an annual report, audit report, earnings release, or any other financial report type. Given the content and nature, this fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2021-03-15 Chinese
昆药集团2020年社会责任报告
Environmental & Social Information Classification · 95% confidence The document is titled '2020年度社会责任报告' which translates to '2020 Annual Social Responsibility Report' of Kunming Pharmaceutical Group Co., Ltd. It contains detailed information about the company's social responsibility activities, environmental initiatives, employee welfare, community engagement, and governance structure. The report covers the period from January 1, 2020 to December 31, 2020. It references compliance with environmental disclosure guidelines and sustainability reporting standards such as GRI. The content focuses on Environmental, Social, and Governance (ESG) factors and corporate social responsibility practices rather than financial results or audit opinions. The length of the document (15,000 characters) and the detailed narrative confirm it is a full report rather than a brief announcement. Therefore, the document fits the category of Environmental & Social Information (Code: SR).
2021-03-15 Chinese
昆药集团关于公司2020年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the company's 2020 annual profit distribution plan. It details the dividend payout per share, total dividend amount, and related financial figures audited by an accounting firm. The announcement also includes the board of directors' meeting results, independent directors' opinions, and supervisory board opinions on the profit distribution plan. The document explicitly states that the profit distribution plan will be submitted to the shareholders' meeting for approval. The content focuses on dividend distribution details rather than the full annual report or financial statements. The document length is 2161 characters, which is relatively short and typical for a dividend announcement rather than a full report. Therefore, this document fits the category of a Notice of Dividend Amount (DIV) rather than an Annual Report or Earnings Release.
2021-03-15 Chinese
关于公司全资子公司昆药集团医药商业有限公司收购的部分子公司2020年度业绩承诺实现情况及处理方案的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the performance fulfillment and handling plans related to the acquisition of subsidiaries by its wholly-owned subsidiary. It discusses specific financial performance commitments (net profit targets) for the years 2017-2021 for several acquired companies, the achievement status of these commitments, compensation clauses, and corrective measures. The document is not a full annual or interim financial report but rather a disclosure about acquisition-related performance commitments and their fulfillment status. It is a regulatory announcement about acquisition performance and related compensation, not a financial statement or earnings release. This fits best under the category of Regulatory Filings (RNS), as it is a compliance disclosure related to acquisition performance commitments and compensation, without being a full financial report or earnings release.
2021-03-15 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.